Ewing Sarcoma Market

LAS VEGAS , NEVADA , UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight’s “Ewing Sarcoma Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as Ewing Sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Ewing Sarcoma Market Research Report
• According to DelveInsight’s analysis, men are more frequently effected than women (with 3:2), in case of Ewing Sarcoma.
• According to SEER registry, it is predominantly observed in populations of European descent with an estimated incidence of ~1.5 cases per million children and adolescents and young adults, for which a genetic explanation has been proposed.
• The leading Ewing Sarcoma Companies working in the market include Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.
• Promising Ewing Sarcoma Pipeline Therapies in the various states of development include Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others.
• March 2024: Pfizer announced a study of Phase 1 & 2 clinical trials for Palbociclib, Temozolomide, Irinotecan, and Topotecan. A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma.
• March 2024: Bayer announced a stuyd of Phase 1 clinical trials for Regorafenib (BAY73-4506), Vincristine (Cellcristin^®), and Irinotecan (Irinotecan Cell pharm^®). A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy.

Discover which therapies are expected to grab the Ewing Sarcoma market share @ Ewing Sarcoma Market Outlook

Ewing Sarcoma Overview
Ewing's sarcoma also known as peripheral primitive neuroectodermal tumor, Ask in tumor, extraosseous Ewing sarcoma, and Ewing sarcoma family of tumors is a malignant tumor that usuallybegins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing's sarcoma can develop in any bone, it usually affects the long bones, like femur, tibia, humerus, and the bones of pelvis. Occasionally, this tumor begins in the muscles and soft tissues (known as extra-osseous Ewing's sarcoma).

Ewing Sarcoma Epidemiology Segmentation in the 7MM
• Ewing Sarcoma Incident Cases
• Ewing Sarcoma Age-Specific Cases
• Ewing Sarcoma Subtype-specific Cases
• Ewing Sarcoma Treatable Cases
• Ewing Sarcoma Gender-Specific Cases

Download the report to understand which factors are driving Ewing Sarcoma epidemiology trends @ Ewing Sarcoma Epidemiological Insights

Ewing Sarcoma Market Dynamics
The Ewing Sarcoma market dynamics is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2023─2032. Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level are Tyme, Gradalis, Oncurious, Eisai, and others.

Ewing Sarcoma Drugs Uptake
Vigil (Gradalis) is a fully personalized cellular immunotherapy being examined for the treatment of advanced cancers with major focus on recurrent or refractory Ewing’s sarcoma. Vigil combines genetic engineering with immuno-oncology to stimulate an immune response against cancer cells. The cells from the tumor are genetically modified in two ways. First, the cells are modified to inhibit the production of furin protein that makes it difficult for the immune system to detect cancer cells. Second, cells are modified to produce granulocyte macrophage colony-stimulating factor (GM-CSF). Phase I study revealed clinical benefit with a median survival of two years. While the median OS of patients in the Phase II study, treated with the combination of Vigil, Irinotecan, and Temozolomide was not met; however, favorable eventfree survival was observed. It is currently under phase III trial and the estimated completion date of this study is December 2022.

Eribulin mesylate (Eisai) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action and inhibit the growth phase of microtubule dynamics, with increased vascular perfusion and permeability in tumor cores. It is currently under phase II trial for Ewing Sarcoma. In pre-clinical studies, eribulin showed broad-spectrum cytotoxicity and had low IC50 values when tested using a large panel of cancer cell lines. This investigational molecule has completed Phase II trial an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) in January 2022.

SM-88 (Tyme) is a novel, oral, investigational agent evaluated as maintenance therapy in combination with methoxsalen, phenytoin. SM88 is an exclusive dysfunctional tyrosine derivative and is the backbone of SM-88 used with MPS. It is designed to be absorbed by the cancer cell as if it were a functional tyrosine, but after uptake it interrupts the processes of protein synthesis, with key targeting of mucin 1. it is currently under phase II trial for Ewing Sarcoma and the estimated completion of this study is by 2022.

Seclidemstat (Salarius Pharmaceuticals) is a small molecule designed to inhibit lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression. LSD1 has been implicated in various types of cancer, with higher levels of LSD1 associated with poor patient prognosis. Seclidemstat (SP 2577) has been shown to inhibit LSD1's demethylation and scaffolding properties and has demonstrated potent therapeutic activity in preclinical models of Ewing sarcoma, a rare pediatric/adolescent bone cancer. It is currently under Phase I clinical trial and the expected completion date of this study in September 2023.

Ewing Sarcoma Treatment Market
The Ewing sarcoma treatment is primarily determined by where it is located in the body and how far it has spread when it is discovered. Vincristine, doxorubicin, ifosfamide, and etoposide are always included in multidrug chemotherapy for Ewing sarcoma. Most protocols also include cyclophosphamide and, in some cases, actinomycin. The mode of administration and dose intensity of cyclophosphamide within courses varies significantly across protocols.

Ewing Sarcoma Market Insights
Ewing sarcoma treatment approaches and therapeutic aggressiveness must be adjusted to maximize local control while minimizing morbidity. The most common method of local control is surgery. In cases where the functional or cosmetic morbidity of surgery is deemed too high by experienced surgical oncologists, radiation therapy is an effective alternative modality for local control. However, in the immature skeleton, radiation therapy can result in deformities that are more morbid than surgical deformities. Postoperative radiation therapy is indicated when complete surgical resection with pathologically negative margins cannot be obtained.

Scope of the Ewing Sarcoma Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Ewing Sarcoma Companies- Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.
• Ewing Sarcoma Pipeline Therapies- Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others.
• Ewing Sarcoma Market Dynamics: Ewing Sarcoma Market Drivers and Barriers
• Ewing Sarcoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Ewing Sarcoma Drugs in development @ Ewing Sarcoma Ongoing Clinical Trials Analysis

Table of Content
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF EWING SARCOMA
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. EWING SARCOMA MARKET OVERVIEW AT A GLANCE
7. DISEASE BACKGROUND AND OVERVIEW
8. TREATMENT MANAGEMENT OF EWING SARCOMA
9. TREATMENT GUIDELINES FOR EWING SARCOMA
10. EPIDEMIOLOGY AND PATIENT POPULATION
11. PATIENT JOURNEY
12. KEY ENDPOINTS IN EWING SARCOMA
13. EMERGING DRUGS
14. EWING SARCOMA: 7MM MARKET ANALYSIS
15. UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.